Quantcast

Latest H5N1 clinical trials Stories

2014-06-12 08:30:25

VIENNA, June 12, 2014 /PRNewswire/ -- A prophylactic vaccine candidate against Chikungunya fever, developed by the Austrian biotech company Themis Bioscience GmbH induces a significant neutralizing immune response and was also confirmed as safe. These are the major interim results of a phase 1 clinical study of the company's Chikungunya vaccine candidate that uses a standard anti-measles vaccine as a vector. The Chikungunya epidemic, currently raging through the Caribbean,...

Parasite-Blocking Antigen Discovery May Lead To Malaria Vaccine
2014-05-23 08:37:58

[ Watch the Video: Protein May Lead To Malaria Vaccine ] Lawrence LeBlond for redOrbit.com - Your Universe Online Malaria remains a dangerous disease in the developing world, killing more than 627,000 people a year, according to the World Health Organization (WHO). Because most deaths associated with malaria occur in children in Sub-Saharan Africa, finding a vaccine against the deadly virus is all too important. New research, by a team from Rhode Island Hospital (RIH), has uncovered...

2014-05-19 08:28:22

Results indicate vaccine generates an immune response against key toxins in volunteers and establish dosing for Phase III BOSTON, May 19, 2014 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), presented Phase II trial (H-030-012) results for an investigational vaccine for the prevention of Clostridium difficile (C. diff) infection (CDI) at the 114th General Meeting of the American Society for Microbiology (ASM). The Phase II trial met its...

2014-04-02 16:31:07

ROCKVILLE, Md., April 2, 2014 /PRNewswire-USNewswire/ -- Sanaria received the 2014 Vaccine Industry Excellence Award for the "Best Prophylactic Vaccine" at a ceremony held March 25 in Washington DC during the 14th World Vaccine Congress. Vaccines from Sanofi Pasteur, GSK, and Novartis were among the 6 finalists competing with Sanaria. The awardee, Sanaria® PfSPZ Vaccine, demonstrated complete protection against malaria in all volunteers (6/6) who received high dose immunizations in a...

2014-03-20 16:26:59

DUBLIN, March 20, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/n8dfqv/china_influenza) has announced the addition of the "China Influenza Vaccine Industry Report 2014" [http://www.researchandmarkets.com/research/n8dfqv/china_influenza ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The China Influenza Vaccine Industry Report 2014 is a professional and in-depth study on the...

2014-02-28 14:04:34

Findings May Help Make Immunizations More Effective Somali Americans develop twice the antibody response to rubella from the current vaccine compared to Caucasians in a new Mayo Clinic study on individualized aspects of immune response. A non-Somali, African-American cohort ranked next in immune response, still significantly higher than Caucasians, and Hispanic Americans in the study were least responsive to the vaccine. The findings appear in the journal Vaccine. “This is...

2014-02-26 16:26:54

Study shows vaccine provides protection against EV71-associated hand, foot and mouth disease in infants and young children BEIJING, Feb. 26, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71") vaccine have been published online in the February 27(th) issue of The New England Journal of Medicine ("NEJM"). The clinical results...

2014-01-29 00:20:55

SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the Phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent...

2013-11-05 23:24:26

The results show that Colby’s JVRS-100 adjuvant, when used in combination with an influenza virus vaccine, generates enhanced immunity and superior protection of elderly monkeys when challenged with live human flu virus (relative to the vaccine alone). San Jose, CA (PRWEB) November 05, 2013 Colby Pharmaceutical Company (CPC) announces ground-breaking results demonstrating that two inoculations of Colby’s JVRS-100 adjuvant, in combination with Fluzone influenza vaccine, enhance the...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.